Emerging Business Models in the Pharmaceutical Industries ...

Long Term Strategies - Biotech and Genomics
Genomics and Proteomics: Higher Efficacy and
Prediction Leading to Disease Management
Eight of the 10 major causes of death in the US have
genetic components. Genomics has evolved as a means of
more effective personalised treatment.
Advances in genomics and proteomics will allow patients to
undergo predictive and preventive diagnostic tests for more
than 750 known conditions. In genomic-based treatment,
chronic and predictable diseases will be treated as normal,
while acute and non-specific conditions will be considered
more risky and profitable for the biotech companies.
Pharma companies are focussing on streamlining genomic
mapping. There are 76 approved biotechnology medicines
today, with more than 360 in the pipeline targeting over 200
diseases.
Nano Technology: Exploring New Drug Delivery
Mechanisms
Pharma companies are considering the use of
nanotechnology to augment the value of an original
invention. Nano technologies help improve drug delivery,
and extend the life of the drug. According to physicist and
entrepreneur Michael Roukes, nano technologies facilitate
medical care tailored explicitly and exactly to the individual.
The emerging technology will provide a new approach for the
investigation of complex biological systems, measuring drug
effects, predicting outcomes like silico, and improving the
R&D and manufacturing processes.
Nano technology is being further developed in these areas:
• Microarrays/GeneChips
• Microfluidics
• Biosensors
• Imaging
• High throughput DNA sequencing
• Database mining
• Genome assembly
• Target identification.
Emerging technologies such as proteomics, biochips, signal
transduction and toxicogenomics are changing the drug
discovery landscape and creating new opportunities for
pharmaceutical, biotechnology and other health-related
companies.
Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 26